Recherchemedicale.com
Tumeurs
Tumeurs par type histologique
Tumeurs embryonnaires et germinales
Carcinome embryonnaire
Carcinome embryonnaire : Questions médicales fréquentes
Diagnostic
5
Carcinome embryonnaire
Biopsie
Imagerie médicale
Marqueurs tumoraux
Alpha-fœtoprotéine
Tests sanguins
Imagerie médicale
IRM
Tomodensitométrie
Biopsie
Diagnostic
Carcinome embryonnaire
Tests génétiques
Carcinome embryonnaire
Prénatal
Symptômes
5
Symptômes
Douleurs abdominales
Tumeurs
Fatigue
Carcinome embryonnaire
Symptômes
Symptômes
Gonflement testiculaire
Carcinome embryonnaire
Symptômes
Douleurs pelviennes
Carcinome embryonnaire
Stades du cancer
Symptômes
Carcinome embryonnaire
Prévention
5
Prévention
Suivi médical
Carcinome embryonnaire
Facteurs génétiques
Carcinome embryonnaire
Antécédents familiaux
Éducation sur le cancer
Dépistage précoce
Carcinome embryonnaire
Habitudes de vie
Prévention
Carcinome embryonnaire
Dépistage
Carcinome embryonnaire
Prévention
Traitements
5
Chirurgie
Chimiothérapie
Radiothérapie
Chirurgie
Carcinome embryonnaire
Traitement
Chimiothérapie
Cisplatine
Étoposide
Radiothérapie
Carcinome embryonnaire
Métastases
Essais cliniques
Thérapies ciblées
Immunothérapie
Complications
5
Complications
Propagation du cancer
Effets secondaires
Métastases
Carcinome embryonnaire
Ganglions lymphatiques
Effets secondaires
Chimiothérapie
Carcinome embryonnaire
Gestion des complications
Suivi médical
Carcinome embryonnaire
Qualité de vie
Soins palliatifs
Complications
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Anomalies congénitales
Âge
Carcinome embryonnaire
Facteurs de risque
Anomalies testiculaires
Carcinome embryonnaire
Facteurs de risque
Tabagisme
Facteurs de risque
Carcinome embryonnaire
Traitements antérieurs
Carcinome embryonnaire
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carcinome embryonnaire : Questions médicales les plus fréquentes",
"headline": "Carcinome embryonnaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carcinome embryonnaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-06",
"dateModified": "2024-12-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carcinome embryonnaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs embryonnaires et germinales",
"url": "https://recherchemedicale.com/mesh/D009373",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs embryonnaires et germinales",
"code": {
"@type": "MedicalCode",
"code": "D009373",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.465"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Carcinome embryonnaire",
"alternateName": "Carcinoma, Embryonal",
"code": {
"@type": "MedicalCode",
"code": "D018236",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Akifumi Muramoto",
"url": "https://recherchemedicale.com/author/Akifumi%20Muramoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan."
}
},
{
"@type": "Person",
"name": "So Inamura",
"url": "https://recherchemedicale.com/author/So%20Inamura",
"affiliation": {
"@type": "Organization",
"name": "Department of Tumor Pathology."
}
},
{
"@type": "Person",
"name": "Hitomi Hoshino",
"url": "https://recherchemedicale.com/author/Hitomi%20Hoshino",
"affiliation": {
"@type": "Organization",
"name": "Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan."
}
},
{
"@type": "Person",
"name": "Naoki Terada",
"url": "https://recherchemedicale.com/author/Naoki%20Terada",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan."
}
},
{
"@type": "Person",
"name": "Motohiro Kobayashi",
"url": "https://recherchemedicale.com/author/Motohiro%20Kobayashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Paradoxical Expression of R-10G-reactive Antigen in Human Testicular Embryonal Carcinoma.",
"datePublished": "2023-09-07",
"url": "https://recherchemedicale.com/article/37675782",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1369/00221554231199134"
}
},
{
"@type": "ScholarlyArticle",
"name": "H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma.",
"datePublished": "2023-01-24",
"url": "https://recherchemedicale.com/article/36706585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prp.2023.154337"
}
},
{
"@type": "ScholarlyArticle",
"name": "Activation of estrogen receptor ESR1 and ESR2 induces proliferation of the human testicular embryonal carcinoma NT2/D1 cells.",
"datePublished": "2022-07-02",
"url": "https://recherchemedicale.com/article/35792284",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.mce.2022.111708"
}
},
{
"@type": "ScholarlyArticle",
"name": "Updating germ cell tumour pathogenesis - the ability of seminomas for FOXA2-driven extra-embryonic differentiation.",
"datePublished": "2023-06-02",
"url": "https://recherchemedicale.com/article/37265221",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14933"
}
},
{
"@type": "ScholarlyArticle",
"name": "Primary embryonal carcinoma of the prostate.",
"datePublished": "2023-12-17",
"url": "https://recherchemedicale.com/article/38205041",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eucr.2023.102640"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://recherchemedicale.com/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://recherchemedicale.com/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs embryonnaires et germinales",
"item": "https://recherchemedicale.com/mesh/D009373"
},
{
"@type": "ListItem",
"position": 5,
"name": "Carcinome embryonnaire",
"item": "https://recherchemedicale.com/mesh/D018236"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carcinome embryonnaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carcinome embryonnaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-02-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carcinome embryonnaire",
"description": "Comment diagnostique-t-on un carcinome embryonnaire ?\nQuels tests sanguins sont utilisés ?\nLes examens d'imagerie sont-ils nécessaires ?\nQuelle est l'importance de la biopsie ?\nPeut-on détecter le carcinome embryonnaire prénatalement ?",
"url": "https://recherchemedicale.com/mesh/D018236#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carcinome embryonnaire",
"description": "Quels sont les symptômes courants ?\nLe carcinome embryonnaire cause-t-il de la fatigue ?\nY a-t-il des symptômes spécifiques chez les hommes ?\nLes femmes ressentent-elles des symptômes différents ?\nLes symptômes varient-ils selon le stade ?",
"url": "https://recherchemedicale.com/mesh/D018236#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carcinome embryonnaire",
"description": "Peut-on prévenir le carcinome embryonnaire ?\nLes facteurs génétiques jouent-ils un rôle ?\nL'éducation sur le cancer est-elle utile ?\nLes habitudes de vie influencent-elles le risque ?\nLe dépistage régulier est-il recommandé ?",
"url": "https://recherchemedicale.com/mesh/D018236#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carcinome embryonnaire",
"description": "Quels traitements sont disponibles ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels médicaments sont utilisés en chimiothérapie ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements expérimentaux ?",
"url": "https://recherchemedicale.com/mesh/D018236#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carcinome embryonnaire",
"description": "Quelles complications peuvent survenir ?\nLe carcinome embryonnaire peut-il métastaser ?\nQuels effets secondaires sont fréquents ?\nComment gérer les complications ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://recherchemedicale.com/mesh/D018236#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carcinome embryonnaire",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes anomalies testiculaires augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes traitements antérieurs au cancer influencent-ils le risque ?",
"url": "https://recherchemedicale.com/mesh/D018236#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un carcinome embryonnaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des examens d'imagerie, des analyses sanguines et une biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux comme l'alpha-fœtoprotéine (AFP) sont souvent mesurés."
}
},
{
"@type": "Question",
"name": "Les examens d'imagerie sont-ils nécessaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les échographies, IRM ou tomodensitométrie aident à localiser la tumeur."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet de confirmer la présence de cellules cancéreuses spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on détecter le carcinome embryonnaire prénatalement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent parfois identifier des risques de tumeurs germinales."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs abdominales, des masses et des troubles urinaires."
}
},
{
"@type": "Question",
"name": "Le carcinome embryonnaire cause-t-il de la fatigue ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente en raison de la maladie et des traitements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les hommes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les hommes peuvent présenter des gonflements testiculaires ou des douleurs scrotales."
}
},
{
"@type": "Question",
"name": "Les femmes ressentent-elles des symptômes différents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir des douleurs pelviennes ou des irrégularités menstruelles."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le stade ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver avec l'avancement de la maladie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le carcinome embryonnaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers germinaux peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'éducation sur le cancer est-elle utile ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sensibiliser sur les symptômes et le dépistage précoce peut aider."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des habitudes saines peuvent réduire le risque de nombreux cancers, y compris le carcinome."
}
},
{
"@type": "Question",
"name": "Le dépistage régulier est-il recommandé ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un dépistage régulier peut aider à détecter des anomalies précoces."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, cela dépend de la taille et de l'emplacement de la tumeur."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés en chimiothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents comme le cisplatine et l'étoposide sont couramment prescrits."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la taille des tumeurs et traiter les métastases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques évaluent de nouvelles thérapies ciblées et immunothérapies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la propagation du cancer et des effets secondaires des traitements."
}
},
{
"@type": "Question",
"name": "Le carcinome embryonnaire peut-il métastaser ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut se propager aux ganglions lymphatiques et à d'autres organes."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires sont fréquents ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, et troubles sanguins."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un soutien symptomatique sont essentiels."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent réduire la qualité de vie et nécessiter des soins palliatifs."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des anomalies congénitales et l'âge."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le carcinome embryonnaire est plus fréquent chez les jeunes adultes et adolescents."
}
},
{
"@type": "Question",
"name": "Les anomalies testiculaires augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme le testicule non descendu sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme est associé à divers cancers, mais son lien direct avec le carcinome embryonnaire est moins clair."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs au cancer influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements antérieurs peuvent augmenter le risque de développer d'autres cancers."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 03/12/2024
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Department of Tumor Pathology.
Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacy, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, 525-8577, Japan.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran. saeednejad.l@iums.ac.ir.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Hasheminejad Kidney Center, Iran University of Medical Sciences, (IUMS), Tehran, Iran.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 669, Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 669, Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 669, Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Publications dans "Carcinome embryonnaire" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 669, Vila Clementino, São Paulo, SP, 04039-032, Brazil. Electronic address: csporto@unifesp.br.
Publications dans "Carcinome embryonnaire" :
1 publication dans cette catégorie
Affiliations :
University Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia.
Publications dans "Carcinome embryonnaire" :
1 publication dans cette catégorie
Affiliations :
Department of Urology, Varisano-Klinik, Bad Soden, Germany.
Publications dans "Carcinome embryonnaire" :
1 publication dans cette catégorie
Affiliations :
University Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia.
Publications dans "Carcinome embryonnaire" :
1 publication dans cette catégorie
Affiliations :
University Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia.
Publications dans "Carcinome embryonnaire" :
1 publication dans cette catégorie
Affiliations :
University Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia.
Publications dans "Carcinome embryonnaire" :
1 publication dans cette catégorie
Affiliations :
University Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia.
Publications dans "Carcinome embryonnaire" :
1 publication dans cette catégorie
Affiliations :
University of South Dakota Sanford School of Medicine, Vermillion, South Dakota.
Publications dans "Carcinome embryonnaire" :
Thus far, several monoclonal antibodies directed against cell-surface carbohydrate antigens have been generated. Among them, R-10G reportedly reacts selectively with human embryonic stem and induced p...
Lymphovascular invasion (LVI) is a relevant prognostic factor in germ cell tumors of the testis (GCTT), and it is included in the pT stage. However, its detection on hematoxylin and eosin (H&E) slides...
Nine authors [5 non-uropathologists and 4 uropathologists] independently evaluated 34 consecutive and retrospectively enrolled cases of GCTT. We assessed the inter-observer agreement (Fleiss's Kappa) ...
The inter-observer agreement among uropathologists plus non-uropathologists was fair with both H&E (KF=0.398; p < 0.001) and OCT4/CD34 (KF=0.312; p < 0.001). OCT4/CD34 (KF=0.290; p < 0.001) slightly r...
OCT4/CD34 does not improve the inter-observer agreement for the assessment of LVI in OCT4(+) GCTT. Consensus diagnosis with H&E modifies the LVI status in a significant number of cases, resulting in c...
The aims of the present study were to investigate the expression of the classic estrogen receptors ESR1 and ESR2, the splicing variant ESR1-36 and GPER in human testicular embryonal carcinoma NT2/D1 c...
Testicular germ cell tumours are the most common solid malignancies in young men of age 14-44 years. It is generally accepted that both seminomas and non-seminomas arise from a common precursor, the g...
Extragonadal germ cell tumors originating in the prostate are extremely rare. Thus far, less than 20 cases were described in the literature. To our knowledge, there are no published cases of primary e...
Testicular germ cell tumor (TGCT) is the most common tumor in young men, but molecular signatures, especially the alternative splicing (AS) between its subtypes have not yet been explored....
To investigate the differences between TGCT subtypes, we comprehensively analyzed the data of gene expression, alternative splicing (AS), and somatic mutation in TGCT patients from the TCGA database. ...
We found significant differences between expression and AS in embryonal carcinoma and seminoma, while mixed cell tumors were in between. GO enrichment analyses revealed that both differentially expres...
In conclusion, our analysis revealed the differences in gene expression, AS and somatic mutation among TGCT subtypes, providing a molecular basis for clinical diagnosis and precise therapy of TGCT pat...
In recent years, several studies investigated the complex process called "reprogramming" of seminoma (S) cells. The accepted pathogenetic model is a complex network including SOX2, SOX17, OCT3/4 and P...
We tested 43, 19 and 17 consecutive and retrospectively enrolled cases of GCTT, germ cell neoplasia in situ (GCNIS) and uninvolved background testes (UBT), respectively. SOX2 and PRAME expressions hav...
We found that SOX2 was more expressed by nonseminomatous-GCTT (NS-GCTT) (p < 0.001) and EC (p < 0.001) rather than S; by contrast, PRAME showed an opposite expression profile being expressed by S but ...
SOX2 and PRAME are differentially expressed and specularly modulated during the "reprogramming" of S cells [P-S (high levels of PRAME, no expression/low levels of SOX2) → S-C (intermediate levels of P...
To systematically evaluate evidence on prognostic factors for tumor recurrence in clinical stage I nonseminoma patients other than lymphovascular invasion (LVI)....
We performed a systematic literature search in the biomedical databases Medline (via Ovid) and Cochrane Central Register of Controlled Trials (search period January 2010 to February 2021) for full tex...
Our literature search yielded eleven studies reporting on 20 potential prognostic factors. Results are based on cohort studies of mostly moderate to low quality. Five out of eight studies found a sign...
No additional factors that meet the prognostic value of LVI, especially when determined by immunohistochemistry, could be identified through our systematic search. The presence of EC might serve as a ...
Germ cell neoplasia in situ (GCNIS) is the precursor of both seminomatous and non-seminomatous germ cell tumors. It consists of distended tubules that may have either intratubular seminoma or intratub...
Extragonadal germ cell tumors (EGCT) are a rare entity, most of them being located in the mediastinum and retroperitoneum. Information on these tumors is scarce, requiring carrying out large populatio...
Demographic and clinicopathological features of patients diagnosed with EGCT of the mediastinum and retroperitoneum from 1975 to 2016 were retrieved from the Surveillance, Epidemiology, and End Result...
A total of 1674 patients were included, 1297 (77.5%) of mediastinal origin and 377 (22.5%) of retroperitoneum. Nonseminomatous tumors (56.3%) were slightly more frequent than seminomas (43.7%) with si...
Despite a decreasing incidence observed in recent decades, EGCT continues to represent a challenge for oncologists. The prognosis of choriocarcinoma and embryonal carcinoma of the mediastinum remains ...